Jun 4, 2026, 15:53
Rituximab and Eculizumab in Refractory Antiphospholipid Syndrome – APS Foundation of America
APS Foundation of America shared a post on LinkedIn:
“Rituximab and Eculizumab Show Benefit in Refractory Antiphospholipid Syndrome
Key Point: Across biologic therapies for antiphospholipid syndrome APS), rituximab and eculizumab had the most robust data, while belimumab and daratumumab were promising but supported by very limited early evidence.
‘Ultimately, personalized strategies integrating clinical phenotype, serology, and pathogenic mechanisms may offer the best approach for optimizing care in patients with refractory or complex APS.'”
Read More.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jun 5, 2026, 01:38Hematopoietic X Chromosome Loss May Offer New Insight Into Ovarian Reserve – RBMO
-
Jun 4, 2026, 17:09ESHRE SIG Endometriosis and Endometrial Disorders Launches New Podcast Episode
-
Jun 4, 2026, 17:04June is Uterine Cancer Awareness Month – Foundation for Women’s Cancer
-
Jun 4, 2026, 16:58Giuseppe Caruso: ADC-opoly in endometrial and cervical cancer: Expanding the Board
-
Jun 4, 2026, 16:50Sergio Haimovich: Good Practice Recommendations on Terminology, Classification, and Diagnosis of Adenomyosis
-
Jun 4, 2026, 16:44Richard Flint: Running to Spread Awareness For Antiphospholipid Syndrome
-
Jun 4, 2026, 16:37Karen Synesiou: What Happens to Frozen Embryos, Eggs, and Sperm When Intended Parents Disappear
-
Jun 4, 2026, 16:30Eric Lameignere: The Impact of Sperm Epigenetics on ICSI Outcomes
-
Jun 4, 2026, 16:23Lupus Anticoagulants: A Review of Current Guidelines and Laboratory Practices – Stago